Antonella Sistigu

Istituto di Patologia Generale, Università Cattolica del Sacro Cuore

Affiliated withUniversità Cattolica del Sacro Cuore IRCCS Regina Elena National Cancer Institute Università Cattolica del Sacro Cuore

Research Area

Biography

Antonella Sistigu has not added Biography.
If you are Antonella Sistigu and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title Cited by 19	2021
Publication title	2024

Other Publications

Article	Year
Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. Cytokine & growth factor reviews\| PubMed ID: 28595838	2017
Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. Oncoimmunology\| PubMed ID: 28638743	2017
The added value of type I interferons to cytotoxic treatments of cancer. Cytokine & growth factor reviews\| PubMed ID: 28693974	2017
Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. Cancer immunology research\| PubMed ID: 29622580	2018
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in cell biology\| PubMed ID: 30765144	2019
Assessment of IFN-γ and granzyme-B production by in "sitro" technology. Methods in enzymology\| PubMed ID: 31948559	2020
Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies. Methods in enzymology\| PubMed ID: 32000907	2020
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal for immunotherapy of cancer\| PubMed ID: 32209603	2020
Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. Cells\| PubMed ID: 32290265	2020
Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. Frontiers in immunology\| PubMed ID: 33193295	2020
Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerging topics in life sciences\| PubMed ID: 33525801	2017
Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. Cell death and differentiation\| PubMed ID: 33531658	2021
The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition. Cancers\| PubMed ID: 33921638	2021
The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. Biology\| PubMed ID: 34571733	2021
Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer? Biology\| PubMed ID: 34571790	2021
The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure. Cells\| PubMed ID: 34572009	2021
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nature immunology\| PubMed ID: 36002648	2022
Apoptotic cell death in disease-Current understanding of the NCCD 2023. Cell death and differentiation\| PubMed ID: 37100955	2023
3D cancer models: One step closer to human studies. Frontiers in immunology\| PubMed ID: 37114038	2023
Epigenetics behind tumor immunology: a mini review. Oncogene\| PubMed ID: 37604925	2023
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer. Journal of translational medicine\| PubMed ID: 37996891	2023
In Vitro Evaluation of Cancer Cell Immunogenicity and Antigen-Specific T-Cell Cytotoxicity by Flow Cytometry. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 38070104	2024